SCHEMBL1853430

SCHEMBL1853430

Cc1ccc[c]c1-c1ncccn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C19 P33261 1/20 0.33
NPC1 O15118 4/20 0.32
RAB9A P51151 3/20 0.32
PLAU P00749 1/20 0.32
KDM4E B2RXH2 1/20 0.32
CYP2A6 P11509 1/20 0.32
CLK4 Q9HAZ1 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
L3MBTL1 Q9Y468 3/20 0.31
MAPT P10636 1/20 0.31
TSHR P16473 1/20 0.31
ACHE P22303 1/20 0.31
ADRB2 P07550 1/20 0.30
HSP90AA1 P07900 1/20 0.30
MITF O75030 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135888 0.81 RXRA (0.31) ACHE
SCHEMBL2884608 0.79 ACHE (0.42) CYP1A2CYP3A4CYP2A6TSHRACHE
SCHEMBL4063012 0.79 KDM4E (0.46) CYP1A2NPC1RAB9AKDM4EL3MBTL1
SCHEMBL18982949 0.77 CYP19A1 (0.32) CYP3A4KDM4ECYP2A6MAPTTSHR
SCHEMBL7394471 0.76 PPARA (0.32)
SCHEMBL1586805 0.75 RAB9A (0.31) NPC1RAB9AL3MBTL1SMN1; SMN2
SCHEMBL16719473 0.75 CYP19A1 (0.38) CYP3A4NPC1RAB9AKDM4EL3MBTL1
SCHEMBL7852621 0.73 MAPT (0.39) NPC1RAB9AKDM4ENPSR1MAPT
SCHEMBL7845170 0.72 CYP2D6 (0.34) CYP1A2CYP3A4CYP2C19MAPTHSP90AA1
SCHEMBL2651386 0.72 NISCH (0.44) CYP1A2CYP3A4CYP2C19KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242116-B2 Fused thiazole derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2012-08-14 US disclosed
EP-2035436-B1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2011-05-25 EP disclosed
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-06-03 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071888-A1 PYRROLOTHIAZOLES AS PI3-KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2035436-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-18 EP disclosed
WO-2008001076-A1 FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137302-A1 Fused Thiazole Derivatives as Kinase Inhibitors PI4KA, PDPK1, PIK3CA NOS3 1858/4885NOS1 2732/4885NOS2 3019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.